Navigation Links
Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt
Date:7/22/2014

MORRIS PLAINS, New Jersey, 22. Juli 2014 /PRNewswire/ -- Qforma, ein führender Anbieter moderner Analysen für die Life-Sciences-Industrie, hat die Ernennung von Marcus Bergler zum General Manager Europe bekanntgegeben. Herr Bergler hat die europäischen kommerziellen Aktivitäten von Qforma bereits als Vice President Strategische Lösungen unterstützt. Bevor er sich Qforma anschloss, war er in Positionen als VP Vertrieb und Marketing bei Cegedim Customer Information, als Vertriebsteam-Leiter Deutschland bei IMS Health und als Direktor bei IMS Consulting tätig.

Marcus Bergler verfügt über langjährige internationale Erfahrungen in Datenapplikationen und modernen Analyseverfahren im Life-Sciences-Bereich. Er ist ein Experte für KOL [key opinion leader / Schlüsselakteure] und die Identifizierung von Interessengruppen sowie für Netzwerkabbildung und hat erfolgreich Mitarbeiterteams in einem beratenden Vertriebsumfeld aufgebaut und geleitet. Er ist ein weltweit anerkannter Branchenfachmann und hält regelmäßig Vorträge bzw. publiziert über die Themenbereich KOL und Netzwerkanalyse.

Kilian Weiss, CEO von Qforma erklärte: „Ich freue mich, dass Marcus bei Qforma ist, um das europäische Mitarbeiterteam zu leiten und dazu beizutragen, unsere Produktinnovation voranzutreiben. Insbesondere seine umfassende Erfahrung bei der Verbindung von Daten und Analysen, um für unsere Kunden Werte zu schaffen, wird unsere Stellung als führender Anbieter für Analysen im Gesundheitswesen weiter fördern. Neben der Schaffung eines signifikanten organischen Wachstums werden wir uns darauf konzentrieren, Angebote zu entwickeln, bei denen wir unsere Allianzen mit führenden Industriedienstleistern wie Veeva wirksam einset
'/>"/>

SOURCE Qforma
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Parma Community General Hospital and EMH Healthcare will become part of University Hospitals effective January 1, 2014
2. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
3. TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America
4. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
5. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
6. Allegheny General Hospital Neurosurgeon Receives NIH Grant for Brain Aneurysm Research
7. Allegheny General Hospital Cardiovascular Team Introduces New MRI Capability for Patients with Pacemakers, Implantable Defibrillators
8. Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device
9. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
10. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
11. Syngenta Holds Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... cell culture products, announces the availability of BI’s line of human mesenchymal stem ... these stem cell differentiation media offer a complete system for multipotency evaluation of ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
(Date:7/28/2015)... Nev. , July 28, 2015  PDL BioPharma, ... today announced that the Company will release its second ... 30, 2015, on Wednesday, August 5, 2015, after market ... webcast that day at 4:30 p.m. Eastern Time to ... the call will be available via the webcast link ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... ONTY ) today reported financial results for the three ... product pipeline update. Management will hold a conference call today ... details). , Oncothyreon reported a loss from operations of $2.8 ... with a loss from operations of $3.6 million for the ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: ... and advances a diverse portfolio of promising cancer-related products ... financial results for the first quarter of fiscal 2010, ... quarter, we continued to advance our lead drug nimotuzumab, ...
... MADRID, November 11 Cellerix, a product-focused,biopharmaceutical company ... the successful first closing of its financing round,raising EUR27 ... a select group of new investors. Cellerix completed another,financing ... This round was led by the ...
Cached Biology Technology:Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 3Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 5Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 6Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 7Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12Cellerix Raises EUR27 Million in a First Closing 2
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... of a small segment of DNA in the genome of ... of ancient animals from sea to land, or to later ... evidence" that copied DNA elements known as retroposons could be ... the research, Howard Hughes Medical Institute investigator David Haussler. ...
... the neighborhood bully so your buddy can get some tail ... works for some lizards, it also gives a fascinating peek ... their year on earth looking to reproduce, and their strategies ... edition of the Proceedings of the National Academy of Sciences ...
... along ?a siesta after a hearty lunch is natural, new ... for the first time uncovered how brain cells or 'neurons' ... , The findings ?published in the scientific journal Neuron this ... well as understanding levels of consciousness. , "It has been ...
Cached Biology News:Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4Nice guys do finish first in lizards' evolutionary race 2Why we could all do with a siesta 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: